Skip to main content
iNtRON Biotechnology, Inc. logo

iNtRON Biotechnology, Inc. — Investor Relations & Filings

Ticker · 048530 ISIN · KR7048530000 KO Manufacturing
Open in API
Filings indexed 268 across all filing types
Latest filing 2019-03-07 Regulatory Filings
Country KR South Korea
Listing KO 048530

About iNtRON Biotechnology, Inc.

https://intronbio.com:6001

iNtRON Biotechnology, Inc. is a biotechnology company specializing in solutions for infectious diseases. Its core activities are centered on three main pillars: bio-new drugs, molecular diagnostics, and molecular biology reagents. The company's therapeutic pipeline focuses on developing novel treatments for drug-resistant super-bacteria, creating antibiotic alternatives and other bio-active agents to address the challenge of antimicrobial resistance (AMR). In its diagnostics division, iNtRON develops and manufactures detection kits and assays, primarily based on real-time PCR technology, for the rapid identification of infectious organisms. The company also provides a range of molecular reagents for research and has commercialized antibiotic alternative products for the animal health market.

Recent filings

Filing Released Lang Actions
기타경영사항(특허권취득)(자율공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Intron Biotechnology regarding the acquisition of a patent for an antibacterial protein. It is categorized as a 'General Management Matter' (기타 경영사항) under Korean regulatory disclosure standards. Since it does not fit into specific categories like financial reports, dividends, or director dealings, it falls under the 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement.
2019-03-07 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on the Status of Large Shareholdings' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the share ownership changes of Mirae Asset Global Investments in Intron Biotechnology. Since this is a specific regulatory disclosure regarding significant shareholding thresholds, it falls under the 'Major Shareholding Notification' category.
2019-03-04 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a significant change in financial results (30% or more fluctuation in revenue or profit). This type of filing is a standard 'Earnings Release' (ER) in the Korean market, providing preliminary financial highlights and the reasons for the change before the final audited annual report is published. It is not a full annual report (10-K) or a report publication announcement (RPA), but rather the initial disclosure of financial performance. FY 2018
2019-02-26 Korean
기타경영사항(특허권취득)(자율공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Intron Biotechnology regarding the acquisition of a patent (patent acquisition disclosure). It provides details on the patent name, content, owner, and utilization plans. Since it does not fit into specific categories like financial reports, shareholder meetings, or management changes, it falls under the general regulatory filing category.
2019-02-25 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a formal announcement of preliminary financial results (영업(잠정)실적) for Intron Biotechnology. It provides a table comparing current quarterly performance against previous periods (revenue, operating profit, net income). This is a standard earnings release document, which fits the definition of an Earnings Release (ER) as it provides key financial highlights before the final audited report is published. Q4 2018
2019-02-12 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is a formal announcement regarding the scheduling and details of an upcoming Investor Relations (IR) event (기업설명회). It provides the date, time, location, and purpose of the meeting. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into the specific report categories, it is classified as a Regulatory Filing (RNS) which serves as the fallback for general corporate announcements.
2019-02-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.